EGFR and neoplasm: Additionally, as a main molecular mechanism of resistance to osimertinib, EGFR amplification was acquired in 4.1% (3/74)21 and 10.9% (5/46)23 of patients receiving the first-line treatment of osimertinib by tumor tissue detection.